Researchers have found that patients with stage B heart failure characteristics and type 2 diabetes have impaired functional capacity.

Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.

Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development ...

Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice ...

The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (“ARI”) for the treatment of CNS rare metabolic diseases, including ...

The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (“ARI”) for the treatment of CNS rare metabolic diseases, including ...

Govorestat is an aldose reductase inhibitor (ARI) designed to replace the enzyme that is deficient in people with the disorder, restoring their ability to metabolise galactose. "We are ...